⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 8, 2024

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].

Shuai Wang Wei Wang Xiangwu Zhang Yingjie Zhang Y L Xiong Lei Liu Lianghong Teng

View Full Paper

Ask AI

Bookmark

Share

Abstract

To examine whether immunohistochemistry of methylthioadenosine phosphorylase (MTAP) and p16 could be used to predict the CDKN2A status in various brain tumors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e6b022b6db643587631d08 https://doi.org/10.3760/cma.j.cn112151-20230815-00069

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Methylthioadenosine Phosphorylase (MTAP) and p16 Expression in Melanocytic Nevi and Melanoma with Molecular Correlation2025
2PATH-64. Utility of p16 and MTAP Immunohistochemistry as a Surrogate for <i>CDKN2A/B</i> Homozygous Deletion and Prognostic Indicator in Meningiomas2025
3Integrated assessment of malignancy in <i>IDH</i>‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistry2024 · 8 citations
4Comparing loss of p16 and MTAP expression in detecting <i>CDKN2A</i> homozygous deletion in pleomorphic xanthoastrocytoma2024 · 7 citations
5Immunohistochemical Loss of MTAP as a Diagnostic and Prognostic Surrogate of CDKN2A/B Homozygous Deletion: A Narrative ReviewLiterature Review · 2026